 | • レポートコード：MRC2303I0178 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の治療薬モニタリング市場規模が、予測期間中に年平均7.5%で成長すると予測しています。本書では、治療薬モニタリングの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術別（イムノアッセイ、プロテオーム）分析、薬剤分類別（抗不整脈薬、免疫抑制剤、抗てんかん薬、その他）分析、エンドユーザー別（病院、診断センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Abbott Laboratories、Alpco、Danaher Corporation （Beckman Coulter Inc.）、Bio-Rad Laboratories Inc.、Chromsystems Instruments & Chemicals GmbH、F. Hoffmann-La Roche Ltd、Randox Laboratories Ltd、Siemens Healthcare GmbH、Thermo Fisher Scientificなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の治療薬モニタリング市場規模：技術別 - イムノアッセイの市場規模 - プロテオームの市場規模 ・世界の治療薬モニタリング市場規模：薬剤分類別 - 抗不整脈薬の市場規模 - 免疫抑制剤の市場規模 - 抗てんかん薬の市場規模 - その他薬剤の市場規模 ・世界の治療薬モニタリング市場規模：エンドユーザー別 - 病院における市場規模 - 診断センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の治療薬モニタリング市場規模：地域別 - 北米の治療薬モニタリング市場規模 アメリカの治療薬モニタリング市場規模 カナダの治療薬モニタリング市場規模 メキシコの治療薬モニタリング市場規模 … - ヨーロッパの治療薬モニタリング市場規模 ドイツの治療薬モニタリング市場規模 イギリスの治療薬モニタリング市場規模 フランスの治療薬モニタリング市場規模 … - アジア太平洋の治療薬モニタリング市場規模 中国の治療薬モニタリング市場規模 インドの治療薬モニタリング市場規模 日本の治療薬モニタリング市場規模 … - 中東・アフリカの治療薬モニタリング市場規模 GCC諸国の治療薬モニタリング市場規模 南アフリカの外科用顕微鏡市場規模 … - 南米の治療薬モニタリング市場規模 ブラジルの治療薬モニタリング市場規模 アルゼンチンの治療薬モニタリング市場規模 … - その他地域の治療薬モニタリング市場規模 ・競争状況 ・市場機会・将来の動向 |
The therapeutic drug monitoring market is expected to register a CAGR of 7.5% over the forecast period.
Globally, the COVID-19 pandemic put enormous pressure on the healthcare system. Hospitals were understaffed and overworked. The urgent need for an accurate and rapid diagnosis of SARS-CoV-2 infection was critical as global healthcare systems continue to operate during the COVID-19 pandemic. In particular, serological and immunological testing of infected asymptomatic and symptomatic individuals was in high demand. Thus, COVID-19 impacted the market profoundly. As per the study published in Expert Review of Clinical Immunology in June 2021, enzyme-linked immunosorbent assays (ELISAs), chemiluminescent immunoassays (CLIAs), and lateral flow immunoassays (LFIAs) were the principal methodologies of serology-based tests for the detection of SARS-CoV-2.
Furthermore, according to the study titled “Rapid chromatographic immunoassay-based evaluation of COVID-19,” published in February 2021, rapid chromatographic immunoassay-based test offered quick and accurate detection of COVID-19 and possessed excellent specificity and moderate sensitivity. Thus, the COVID-19 pandemic had a favorable impact on the market initially. As the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period of the study.
Increasing prevalence of cancers, neurological conditions, HIV, autoimmune and cardiac diseases, and growing R&D activities and clinical trials to expand the application of technologies in various indications. In August 2021, the Journal of Clinical Neurology cited epilepsy as the third most common neurological disorder after stroke and dementia, affecting approximately 70 million patients worldwide. According to WHO’s 2021 data, more than 55 million people will live with dementia worldwide. Nearly 10 million new cases will be reported every year. Alzheimer’s disease is the most common form of dementia and may contribute to 60-70% of the cases. Therefore, increasing chances of such diseases are anticipated to propel the market growth over the forecast period.
Moreover, various initiatives by the market players, such as product launches and mergers and acquisitions, are expected to propel the market’s growth. For instance, in May 2022, THERADIAG, a company specializing in vitro diagnostics and theragnostic, reported the launch of ez-Track1, an accurate Point-of-Care Testing (POCT) solution for therapeutic drug monitoring. Such advancement in drug monitoring technology is expected to boost the market over the forecast period.
However, the reluctance of healthcare providers to implement therapeutic drug monitoring services in emerging nations is likely to hinder market growth over the forecast period.
Therapeutic Drug Monitoring Market Trends
Immunoassays Expected to Hold a Significant Market Share
Immunoassays are widely used in many vital areas of pharmaceutical analysis, such as diagnosis of diseases, therapeutic drug monitoring, clinical pharmacokinetics, and bioequivalence studies in drug discovery and pharmaceutical industries. The importance and widespread of immunoassay methods in pharmaceutical analysis are attributed to their inherent specificity, high throughput, and high sensitivity for analyzing a wide range of analytes in biological samples.
The continuous research work and requirements for drug developments in pharmaceutical industries are the major factors contributing to the segment’s growth. For instance, according to the study published by the National Library of Medicine in March 2021, researchers developed a reliable and specific radioimmunoassay method for the measurement of dodecapeptide angiotensin in human plasma and urine using an affinity-purified antibody fraction directed towards the C-terminus of the human Ang-(1–12) sequence. The radioimmunoassay method was applied to quantify the Ang-(1–12) in plasma and urine.
The growing technological advancement in the product is expected to propel the segment’s growth. For instance, in November 2021, Boditech Med launched its new automated immunoassay analyzer with a blood collection tube, including an all-in-one cartridge system, at MEDICA 2021.
Thus, the segment will likely expand over the forecast period due to the aforementioned factors.
North America Holds a Significant Market Share and is Expected to do the Same during the Forecast Period
North America is expected to witness a significant share in the overall therapeutic drug monitoring market over the forecast period. The major market drivers are the increasing incidence rates of chronic disorders and infectious diseases, the rising geriatric population, and the well-developed healthcare infrastructure in the region.
Additionally, according to an article published by the Heart and Stroke Foundation of Canada in February 2022, over 750,000 people in the nation are living with heart failure, and over 100,000 people are diagnosed with a heart condition every year. Such figures are anticipated to propel the market growth over the forecast period in this region.
Key product launches, high concentration of market players or manufacturer’s presence, acquisitions & partnerships among significant players, and increasing cases of chronic diseases in the United States are some of the factors driving the growth of the therapeutic drug monitoring market in the country. For instance, in May 2022, Bamboo Health, formerly Appriss Health and PatientPing, announced a partnership with the Wyoming Board of Pharmacy on June 29 to develop a solution for its Prescription Drug Monitoring Program (PDMP).
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.
Therapeutic Drug Monitoring Market Competitor Analysis
The therapeutic drug monitoring market is moderately competitive and consists of several major players. Some companies are expanding their market position by adopting various strategies, such as acquisitions and mergers, while others are developing new techniques for treating multiple disease indications and introducing new products to maintain their market share. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Danaher Corporation (Beckman Coulter Inc.), and Siemens Healthcare GmbH, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancers, HIV, Autoimmune, and Cardiac Diseases
4.2.2 Growing R&D Activities and Clinical Trials to Increase the Application of Technologies in Various Indications
4.3 Market Restraints
4.3.1 The Reluctance of Healthcare Providers to Implement TDM Services in Emerging Nations
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Technology
5.1.1 Immunoassays
5.1.2 Proteomic Technologies
5.2 By Drug Class
5.2.1 Antiarrhythmic Drugs
5.2.2 Immunosuppressants
5.2.3 Antiepileptic Drugs
5.2.4 Other Drug Classes
5.3 By End-user
5.3.1 Hospitals
5.3.2 Diagnostic Centres
5.3.3 Other End-users
5.4 By Geography
5.4.1 North America
5.4.1.1 United states
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Alpco
6.1.3 Danaher Corporation (Beckman Coulter Inc.)
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Chromsystems Instruments & Chemicals GmbH
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Randox Laboratories Ltd
6.1.8 Siemens Healthcare GmbH
6.1.9 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS